The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwAL 2026 | Optimizing allogeneic transplantation through prospective randomized trials in AML
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, FMedSci, University of Birmingham, Birmingham, UK, discusses the UK IMPACT transplant trials network and the importance of prospective randomized studies in optimizing allogeneic stem cell transplantation for acute myeloid leukemia (AML). He highlights the network’s successful recruitment of more than 1,500 patients to trials evaluating strategies to reduce transplant-related toxicity and relapse, including approaches to graft-versus-host disease and conditioning. This interview took place at the 8th International Workshop on Acute Leukemias (iwAL 2026), held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
